Sanofi, a French-based global pharmaceutical firm, has unveiled an alliance with TrialSpark, a New York-based startup that provides a technology-powered approach to drug development. Both companies are focused on pursuing the purchase or in-licensing of therapeutic candidates in clinical stages II and III that have significant unmet patient needs. The tools from TrialSpark are intended to improve trial design efficiency, trial execution speed, and trial data quality. The company purchases clinical-stage medications from pharmaceutical and biotech firms and further develops them through different technologies. Rheumatology, dermatology, CNS (neurology and psychiatry), and cardiometabolic illnesses are among the therapeutic specialities offered by the organisation.
Read More from MobiHealthNews
